Cathelicidin gene therapy: A new therapeutic option in ulcerative colitis and beyond?

Gene Therapy

Volumn 20, Issue 2, 2013, Pages 119-120

  Ahluwalia, A ^a   Tarnawski, A S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; DEXTRAN SULFATE; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIMICROBIAL ACTIVITY; COLITIS; COLON FLORA; FECES MICROFLORA; GENE THERAPY; INNATE IMMUNITY; INTESTINE EPITHELIUM CELL; MUCUS SECRETION; NEUTROPHIL; NONHUMAN; NOTE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; COLITIS, ULCERATIVE; GENETIC THERAPY;

EID: 84873567814     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.23     Document Type: Note

References (14)

1. Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 2004; 75: 39-48 (Pubitemid 38166778)
2. Zanetti M. The role of cathelicidins in the innate host defenses of mammals. Curr Issues Mol Biol 2005; 7: 179-196 (Pubitemid 41051685)
3. Metz-Boutigue MH, Shooshtarizadeh P, Prevost G, Haikel Y, Chich JF. Antimicrobial peptides present in mammalian skin and gut are multifunctional defence molecules. Curr Pharm Des 2010; 16: 1024-1039
4. Wu WK, Wong CC, Li ZJ, Zhang L, Ren SX, Cho CH. Cathelicidins in inflammation and tissue repair: Potential therapeutic applications for gastrointestinal disorders. Acta Pharmacol Sin 2010; 31: 1118-1122
5. Frasca L, Lande R. Role of defensins and cathelicidin LL37 in auto-immune and auto-inflammatory diseases. Curr Pharm Biotechnol 2012; e-pub ahead of print 17 January 2012
6. Iimura M, Gallo RL, Hase K, Miyamoto Y, Eckmann L, Kagnoff MF. Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens. J Immunol 2005; 174: 4901-4907
7. Schauber J, Dorschner RA, Yamasaki K, Brouha B, Gallo RL. Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli. Immunology 2006; 118: 509-519 (Pubitemid 44079569)
8. Wuerth K, Hancock RE. New insights into cathelicidin modulation of adaptive immunity. Eur J Immunol 2011; 41: 2817-2819
9. Koon HW, Shih DQ, Chen J, Bakirtzi K, Hing TC, Law I et al. Cathelicidin signaling via the toll-like receptor protects against colitis in mice. Gastroenterology 2011; 141: 1852-1863. e3
10. Kucharzik T, Maaser C, Lugering A, Kagnoff M, Mayer L, Targan S, Domschke W. Recent understanding of IBD pathogenesis: Implications for future therapies. Inflamm Bowel Dis 2006; 12: 1068-1083
11. Tai EK, Wu WK, Wong HP, Lam EK, Yu L, Cho CH. A new role for cathelicidin in ulcerative colitis in mice. Exp Biol Med 2007; 232: 799-808 (Pubitemid 46827822)
12. Tai EKK, Wu WKK, Wang XJ, Wong HPS, Yu L, Lia ZJ et al. Intrarectal administration of mCRAMP-encoding plasmid reverses exacerbated colitis in Cnlp-/- mice. Gene Therapy 2012 (this issue).
13. Wehkamp J, Schmid M, Stange EF. Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr Opin Gastroenterol 2007; 23: 370-378 (Pubitemid 46878947)
14. Wong CC, Zhang L, Ren SX, Shen J, Chan RL, Cho CH. Antibacterial peptides and gastrointestinal diseases. Curr Pharm Des 2011; 17: 1583-1586